Results of a multivariate analysis to find prognostic factors for molecular remission post-DLI in 66 patients who relapsed post-allogeneic SCT for CML
| Variable . | No. of patients . | RR . | 95% CI . | P value . |
|---|---|---|---|---|
| Type of relapse at time of DLI | ||||
| Molecular | 8 | 1.00 | ||
| Cytogenetic | 19 | 0.55 | 0.2-1.4 | .21 |
| Hematologic, CP | 30 | 0.24 | 0.1-0.6 | .002 |
| Hematologic, AP | 9 | 0.07 | 0.02-0.44 | .001 |
| Interval SCT to relapse | ||||
| <9 months | 25 | 1.00 | ||
| ≥9 months | 41 | 2.82 | 1.35-5.92 | .006 |
| Donor match | ||||
| HLA-identical sibling | 35 | 1.00 | ||
| Matched unrelated | 31 | 1.91 | 0.78-4.70 | .16 |
| GVHD prophylaxis | ||||
| Non-TCD | 22 | 1.00 | ||
| TCD | 44 | 1.06 | 0.44-2.56 | .89 |
| Variable . | No. of patients . | RR . | 95% CI . | P value . |
|---|---|---|---|---|
| Type of relapse at time of DLI | ||||
| Molecular | 8 | 1.00 | ||
| Cytogenetic | 19 | 0.55 | 0.2-1.4 | .21 |
| Hematologic, CP | 30 | 0.24 | 0.1-0.6 | .002 |
| Hematologic, AP | 9 | 0.07 | 0.02-0.44 | .001 |
| Interval SCT to relapse | ||||
| <9 months | 25 | 1.00 | ||
| ≥9 months | 41 | 2.82 | 1.35-5.92 | .006 |
| Donor match | ||||
| HLA-identical sibling | 35 | 1.00 | ||
| Matched unrelated | 31 | 1.91 | 0.78-4.70 | .16 |
| GVHD prophylaxis | ||||
| Non-TCD | 22 | 1.00 | ||
| TCD | 44 | 1.06 | 0.44-2.56 | .89 |
DLI, donor lymphocyte infusion; SCT, stem cell transplantation; CML, chronic myeloid leukemia; RR, relative risk; CI, confidence interval; CP, chronic phase; AP, advanced phase; GVHD, graft-versus-host disease; TCD, in vitro or in vivo T-cell depletion with Campath (CD52) monoclonal antibodies.